Boston Scientific Corporation (BSX) : Artisan Partners Limited Partnership scooped up 434,740 additional shares in Boston Scientific Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 11, 2016. The investment management firm now holds a total of 41,479,994 shares of Boston Scientific Corporation which is valued at $990,957,057.Boston Scientific Corporation makes up approximately 2.00% of Artisan Partners Limited Partnership’s portfolio.
Other Hedge Funds, Including , Bessemer Group Inc reduced its stake in BSX by selling 2,302 shares or 70.05% in the most recent quarter. The Hedge Fund company now holds 984 shares of BSX which is valued at $23,508. Private Advisor Group added BSX to its portfolio by purchasing 13,985 company shares during the most recent quarter which is valued at $333,962. Boston Scientific Corporation makes up approx 0.01% of Private Advisor Group’s portfolio.Bnp Paribas Investment Partners S.a. boosted its stake in BSX in the latest quarter, The investment management firm added 586,919 additional shares and now holds a total of 2,348,291 shares of Boston Scientific Corporation which is valued at $56,030,223. Boston Scientific Corporation makes up approx 0.48% of Bnp Paribas Investment Partners S.a.’s portfolio.Highland Capital Management reduced its stake in BSX by selling 12,745 shares or 34.72% in the most recent quarter. The Hedge Fund company now holds 23,960 shares of BSX which is valued at $581,270. Boston Scientific Corporation makes up approx 0.05% of Highland Capital Management’s portfolio.
Boston Scientific Corporation closed down -0.01 points or -0.04% at $24.11 with 43,39,079 shares getting traded on Tuesday. Post opening the session at $24.16, the shares hit an intraday low of $24.08 and an intraday high of $24.33 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Boston Scientific Corporation reported $0.27 EPS for the quarter, based on the information available during the earnings call on Jul 28, 2016. Analyst had a consensus estimate of $0.27. The company had revenue of $2126.00 million for the quarter, compared to analysts expectations of $2044.88 million. The company’s revenue was up 15.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.22 EPS.
Many Wall Street Analysts have commented on Boston Scientific Corporation. Company shares were Reiterated by Wedbush on Jul 29, 2016 to “Neutral”, Firm has raised the Price Target to $ 25 from a previous price target of $23 .Company shares were Reiterated by Needham on Jul 29, 2016 to “Buy”, Firm has raised the Price Target to $ 28 from a previous price target of $26 .Company shares were Reiterated by The Benchmark Company on Jul 28, 2016 to “Buy”, Firm has raised the Price Target to $ 31 from a previous price target of $25 .
Boston Scientific Corporation develops manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology which includes Drug-Eluting Coronary Stent Systems Intravascular Imaging devised and Coronary Technology products such as guide wires guide catheters and balloon catheters among others; Peripheral Interventions (PI) which include stents balloon catheters wires peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM) which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP) which include steerable RF ablation catheters intracardiac ultrasound catheters diagnostic catheters delivery sheaths and other accessories; Endoscopy which includes Spyglass System WallFlex Colonic Stents Resolution Clip and Expect Aspiration Needle among others; Urology and Womens Health and Neuromodulation.